Aspirin and clopidogrel high on‐treatment platelet reactivity and genetic predictors in peripheral arterial disease
Objectives Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on‐treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD). Background The association of aspirin and clopidogrel...
Uloženo v:
| Vydáno v: | Catheterization and cardiovascular interventions Ročník 91; číslo 7; s. 1308 - 1317 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Wiley Subscription Services, Inc
01.06.2018
|
| Témata: | |
| ISSN: | 1522-1946, 1522-726X, 1522-726X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Objectives
Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on‐treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD).
Background
The association of aspirin and clopidogrel HoTPR with outcomes in PAD remains unclear.
Methods
This is a prospective cohort study of patients with angiographically documented PAD involving carotid and lower extremity arteries. Aspirin and clopidogrel HoTPR (using the VerifyNow Assay) and associated genetic predictors were compared to clinical outcomes. The primary end‐point was a composite of major adverse cardiovascular events: all‐cause mortality, myocardial infarction, stroke, target vessel revascularization (TVR) and limb‐loss in patients who underwent extremity intervention.
Results
The study was stopped prematurely due to slow patient enrolment. Of 195 patients enrolled, the primary analysis was performed in 154 patients taking both drugs. Aspirin HoTPR was present in 31 (20%) and clopidogrel HoTPR in 76 (49%) patients. There was a trend toward more primary composite outcome events with PRU ≥ 235 (52% freedom‐from‐event rate vs. 70% for PRU < 235; P = 0.09). TVR was higher in those with PRU ≥ 235 (20 vs. 6%, unadjusted P = 0.02). There was no association between aspirin HoTPR and combined outcomes. Single nucleotide polymorphisms in serum paraoxonase/arylesterase 1 (PON1) gene was associated with aspirin HoTPR (P = 0.005) while SNP in phospholipase A2, group III (PLA2G3) gene was associated with clopidogrel HoTPR (P = 0.002).
Conclusion
Clopidogrel HoTPR was significantly associated with TVR, while aspirin HoTPR was not associated with adverse clinical outcomes in patients with PAD. |
|---|---|
| AbstractList | ObjectivesOur aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on‐treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD).BackgroundThe association of aspirin and clopidogrel HoTPR with outcomes in PAD remains unclear.MethodsThis is a prospective cohort study of patients with angiographically documented PAD involving carotid and lower extremity arteries. Aspirin and clopidogrel HoTPR (using the VerifyNow Assay) and associated genetic predictors were compared to clinical outcomes. The primary end‐point was a composite of major adverse cardiovascular events: all‐cause mortality, myocardial infarction, stroke, target vessel revascularization (TVR) and limb‐loss in patients who underwent extremity intervention.ResultsThe study was stopped prematurely due to slow patient enrolment. Of 195 patients enrolled, the primary analysis was performed in 154 patients taking both drugs. Aspirin HoTPR was present in 31 (20%) and clopidogrel HoTPR in 76 (49%) patients. There was a trend toward more primary composite outcome events with PRU ≥ 235 (52% freedom‐from‐event rate vs. 70% for PRU < 235; P = 0.09). TVR was higher in those with PRU ≥ 235 (20 vs. 6%, unadjusted P = 0.02). There was no association between aspirin HoTPR and combined outcomes. Single nucleotide polymorphisms in serum paraoxonase/arylesterase 1 (PON1) gene was associated with aspirin HoTPR (P = 0.005) while SNP in phospholipase A2, group III (PLA2G3) gene was associated with clopidogrel HoTPR (P = 0.002).ConclusionClopidogrel HoTPR was significantly associated with TVR, while aspirin HoTPR was not associated with adverse clinical outcomes in patients with PAD. Objectives Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on‐treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD). Background The association of aspirin and clopidogrel HoTPR with outcomes in PAD remains unclear. Methods This is a prospective cohort study of patients with angiographically documented PAD involving carotid and lower extremity arteries. Aspirin and clopidogrel HoTPR (using the VerifyNow Assay) and associated genetic predictors were compared to clinical outcomes. The primary end‐point was a composite of major adverse cardiovascular events: all‐cause mortality, myocardial infarction, stroke, target vessel revascularization (TVR) and limb‐loss in patients who underwent extremity intervention. Results The study was stopped prematurely due to slow patient enrolment. Of 195 patients enrolled, the primary analysis was performed in 154 patients taking both drugs. Aspirin HoTPR was present in 31 (20%) and clopidogrel HoTPR in 76 (49%) patients. There was a trend toward more primary composite outcome events with PRU ≥ 235 (52% freedom‐from‐event rate vs. 70% for PRU < 235; P = 0.09). TVR was higher in those with PRU ≥ 235 (20 vs. 6%, unadjusted P = 0.02). There was no association between aspirin HoTPR and combined outcomes. Single nucleotide polymorphisms in serum paraoxonase/arylesterase 1 (PON1) gene was associated with aspirin HoTPR (P = 0.005) while SNP in phospholipase A2, group III (PLA2G3) gene was associated with clopidogrel HoTPR (P = 0.002). Conclusion Clopidogrel HoTPR was significantly associated with TVR, while aspirin HoTPR was not associated with adverse clinical outcomes in patients with PAD. Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD).OBJECTIVESOur aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD).The association of aspirin and clopidogrel HoTPR with outcomes in PAD remains unclear.BACKGROUNDThe association of aspirin and clopidogrel HoTPR with outcomes in PAD remains unclear.This is a prospective cohort study of patients with angiographically documented PAD involving carotid and lower extremity arteries. Aspirin and clopidogrel HoTPR (using the VerifyNow Assay) and associated genetic predictors were compared to clinical outcomes. The primary end-point was a composite of major adverse cardiovascular events: all-cause mortality, myocardial infarction, stroke, target vessel revascularization (TVR) and limb-loss in patients who underwent extremity intervention.METHODSThis is a prospective cohort study of patients with angiographically documented PAD involving carotid and lower extremity arteries. Aspirin and clopidogrel HoTPR (using the VerifyNow Assay) and associated genetic predictors were compared to clinical outcomes. The primary end-point was a composite of major adverse cardiovascular events: all-cause mortality, myocardial infarction, stroke, target vessel revascularization (TVR) and limb-loss in patients who underwent extremity intervention.The study was stopped prematurely due to slow patient enrolment. Of 195 patients enrolled, the primary analysis was performed in 154 patients taking both drugs. Aspirin HoTPR was present in 31 (20%) and clopidogrel HoTPR in 76 (49%) patients. There was a trend toward more primary composite outcome events with PRU ≥ 235 (52% freedom-from-event rate vs. 70% for PRU < 235; P = 0.09). TVR was higher in those with PRU ≥ 235 (20 vs. 6%, unadjusted P = 0.02). There was no association between aspirin HoTPR and combined outcomes. Single nucleotide polymorphisms in serum paraoxonase/arylesterase 1 (PON1) gene was associated with aspirin HoTPR (P = 0.005) while SNP in phospholipase A2, group III (PLA2G3) gene was associated with clopidogrel HoTPR (P = 0.002).RESULTSThe study was stopped prematurely due to slow patient enrolment. Of 195 patients enrolled, the primary analysis was performed in 154 patients taking both drugs. Aspirin HoTPR was present in 31 (20%) and clopidogrel HoTPR in 76 (49%) patients. There was a trend toward more primary composite outcome events with PRU ≥ 235 (52% freedom-from-event rate vs. 70% for PRU < 235; P = 0.09). TVR was higher in those with PRU ≥ 235 (20 vs. 6%, unadjusted P = 0.02). There was no association between aspirin HoTPR and combined outcomes. Single nucleotide polymorphisms in serum paraoxonase/arylesterase 1 (PON1) gene was associated with aspirin HoTPR (P = 0.005) while SNP in phospholipase A2, group III (PLA2G3) gene was associated with clopidogrel HoTPR (P = 0.002).Clopidogrel HoTPR was significantly associated with TVR, while aspirin HoTPR was not associated with adverse clinical outcomes in patients with PAD.CONCLUSIONClopidogrel HoTPR was significantly associated with TVR, while aspirin HoTPR was not associated with adverse clinical outcomes in patients with PAD. Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD). The association of aspirin and clopidogrel HoTPR with outcomes in PAD remains unclear. This is a prospective cohort study of patients with angiographically documented PAD involving carotid and lower extremity arteries. Aspirin and clopidogrel HoTPR (using the VerifyNow Assay) and associated genetic predictors were compared to clinical outcomes. The primary end-point was a composite of major adverse cardiovascular events: all-cause mortality, myocardial infarction, stroke, target vessel revascularization (TVR) and limb-loss in patients who underwent extremity intervention. The study was stopped prematurely due to slow patient enrolment. Of 195 patients enrolled, the primary analysis was performed in 154 patients taking both drugs. Aspirin HoTPR was present in 31 (20%) and clopidogrel HoTPR in 76 (49%) patients. There was a trend toward more primary composite outcome events with PRU ≥ 235 (52% freedom-from-event rate vs. 70% for PRU < 235; P = 0.09). TVR was higher in those with PRU ≥ 235 (20 vs. 6%, unadjusted P = 0.02). There was no association between aspirin HoTPR and combined outcomes. Single nucleotide polymorphisms in serum paraoxonase/arylesterase 1 (PON1) gene was associated with aspirin HoTPR (P = 0.005) while SNP in phospholipase A2, group III (PLA2G3) gene was associated with clopidogrel HoTPR (P = 0.002). Clopidogrel HoTPR was significantly associated with TVR, while aspirin HoTPR was not associated with adverse clinical outcomes in patients with PAD. |
| Author | Westin, Gregory G. Anderson, David Armstrong, Ehrin J. Yeo, Khung‐Keong Li, Chin‐Shang Hua, Amy Chiamvimonvat, Nipavan Laird, John R. Amsterdam, Ezra A. López, Javier E. Chen, Debbie C. Singapuri, Anil |
| AuthorAffiliation | 3 Division of Cardiology, VA Eastern Colorado Healthcare System, CO 1 Division of Cardiovascular Medicine and the Vascular Center, University of California, Davis, CA 9 Department of Veterans Affairs, Northern California Health Care System, Mather, CA 5 Department of Medicine, Massachusetts General Hospital, Boston, MA 7 Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA 8 Department of Internal Medicine, University of California, San Francisco, CA 6 Division of Vascular and Endovascular Surgery, NYU Langone Medical Center, New York, NY 4 Division of Cardiovascular Medicine, University of California, Davis, CA 2 Department of Cardiology, National Heart Centre Singapore, Singapore |
| AuthorAffiliation_xml | – name: 6 Division of Vascular and Endovascular Surgery, NYU Langone Medical Center, New York, NY – name: 7 Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA – name: 2 Department of Cardiology, National Heart Centre Singapore, Singapore – name: 8 Department of Internal Medicine, University of California, San Francisco, CA – name: 1 Division of Cardiovascular Medicine and the Vascular Center, University of California, Davis, CA – name: 4 Division of Cardiovascular Medicine, University of California, Davis, CA – name: 5 Department of Medicine, Massachusetts General Hospital, Boston, MA – name: 9 Department of Veterans Affairs, Northern California Health Care System, Mather, CA – name: 3 Division of Cardiology, VA Eastern Colorado Healthcare System, CO |
| Author_xml | – sequence: 1 givenname: Khung‐Keong orcidid: 0000-0002-5457-4881 surname: Yeo fullname: Yeo, Khung‐Keong organization: National Heart Centre Singapore – sequence: 2 givenname: Ehrin J. orcidid: 0000-0002-5682-8363 surname: Armstrong fullname: Armstrong, Ehrin J. organization: VA Eastern Colorado Healthcare System – sequence: 3 givenname: Javier E. surname: López fullname: López, Javier E. organization: University of California – sequence: 4 givenname: Debbie C. surname: Chen fullname: Chen, Debbie C. organization: Massachusetts General Hospital – sequence: 5 givenname: Gregory G. surname: Westin fullname: Westin, Gregory G. organization: NYU Langone Medical Center – sequence: 6 givenname: Chin‐Shang surname: Li fullname: Li, Chin‐Shang organization: University of California – sequence: 7 givenname: David surname: Anderson fullname: Anderson, David organization: University of California – sequence: 8 givenname: Amy surname: Hua fullname: Hua, Amy organization: University of California – sequence: 9 givenname: Anil surname: Singapuri fullname: Singapuri, Anil organization: University of California – sequence: 10 givenname: Ezra A. surname: Amsterdam fullname: Amsterdam, Ezra A. organization: University of California – sequence: 11 givenname: Nipavan surname: Chiamvimonvat fullname: Chiamvimonvat, Nipavan organization: Northern California Health Care System – sequence: 12 givenname: John R. surname: Laird fullname: Laird, John R. email: Lairdjr@ah.org organization: University of California |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29411531$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kcuKVDEQhoOMOBdd-AJywI0ueiaXk-RkIwztFQbcKLgL6aS6O0M6OSY5I73zEXxGn8T0dDvogC5CqpLv_6niP0VHMUVA6CnB5wRjemGtO6ey5-wBOiGc0pmk4svRoSaqF8fotJRrjLESVD1Cx1T1hHBGTtB0WUaffexMdJ0NafQurTKEbu1X6y7Fn99_1AymbiDWbgymQoDatRdb_Y2v21vdCiJUb7sxg_O2ply65jhC9uMasgmdybU1rXC-gCnwGD1cmlDgyeE-Q5_fvvk0fz-7-vjuw_zyamb7nrGZUsNSAO6HQYACQnvmsFkIxa3jWC0H5yQZesGF5APjoBZYMsYEXWAMUlrBztCrve84LTbgbFuijaPH7Dcmb3UyXv_9E_1ar9KN5kpJTnEzeHEwyOnrBKXqjS8WQjAR0lQ0UUrtDt6hz--h12nKsa2nKeaMi54MslHP_pzobpTfiTTg5R6wOZWSYXmHEKx3aeuWtr5Nu7EX91jrq6k-7Zbx4X-Kbz7A9t_Wej5_vVf8AnWqvTA |
| CitedBy_id | crossref_primary_10_2459_JCM_0000000000001406 crossref_primary_10_1016_j_ejvs_2018_06_032 crossref_primary_10_26453_otjhs_905082 crossref_primary_10_1016_j_ejvs_2021_10_045 crossref_primary_10_1016_j_thromres_2024_02_010 crossref_primary_10_2147_IJGM_S450059 crossref_primary_10_1080_09537104_2020_1742314 crossref_primary_10_1016_j_avsg_2022_12_071 crossref_primary_10_1177_17085381231214324 crossref_primary_10_2147_PGPM_S279719 crossref_primary_10_1186_s12959_022_00445_4 crossref_primary_10_1093_ajhp_zxac095 crossref_primary_10_1016_j_vph_2021_106925 |
| Cites_doi | 10.1111/j.1742-1241.2007.01344.x 10.1111/j.1538-7836.2007.02656.x 10.1016/j.amjmed.2005.03.041 10.1038/nm.2281 10.1111/j.1538-7836.2008.03184.x 10.1146/annurev.med.54.101601.152421 10.1056/NEJMc090391 10.1016/j.amjcard.2004.11.045 10.1007/s00270-013-0710-3 10.1160/TH07-09-0575 10.1093/eurheartj/ehn046 10.1016/j.jacc.2013.03.036 10.1055/s-0037-1614250 10.1002/cncr.21979 10.1016/j.jacc.2008.06.038 10.1161/CIR.0b013e31828b82aa 10.1006/geno.1996.0401 10.1161/01.CIR.104.2.140 10.1111/j.1399-0004.2008.01105.x 10.1016/S0306-3623(98)00028-7 10.1056/NEJMoa0808227 10.1161/01.CIR.103.6.e33 10.1056/NEJMoa0809171 10.1016/j.jacc.2011.08.023 10.1016/j.jacc.2016.11.007 10.1016/j.thromres.2011.04.010 10.1309/0G1PEJ00J8KP8357 10.1161/CIRCULATIONAHA.108.812636 10.1160/TH05-07-0516 10.1016/S0140-6736(97)80010-4 10.1161/CIRCULATIONAHA.110.936393 10.1016/0049-3848(93)90164-J 10.1016/j.amjmed.2006.10.021 10.1023/A:1022066305399 10.1007/s00439-011-1130-6 10.1016/j.jvs.2010.08.029 10.1016/S0140-6736(98)06448-4 10.1016/S0140-6736(06)68040-9 10.1016/j.ahj.2004.03.028 10.1055/s-0038-1657677 10.1016/S0735-1097(02)03014-0 |
| ContentType | Journal Article |
| Copyright | 2018 Wiley Periodicals, Inc. |
| Copyright_xml | – notice: 2018 Wiley Periodicals, Inc. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 K9. 7X8 5PM |
| DOI | 10.1002/ccd.27453 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1522-726X |
| EndPage | 1317 |
| ExternalDocumentID | PMC5997520 29411531 10_1002_ccd_27453 CCD27453 |
| Genre | article Journal Article Observational Study |
| GeographicLocations | California |
| GeographicLocations_xml | – name: California |
| GrantInformation_xml | – fundername: American Heart Association Clinical Research Award, NIH funderid: R01 HL085727 ; R01 HL137228 ; R01 HL085844 – fundername: National Institutes of Health (NIH) funderid: UL1 TR000002; UL1 TR001860 – fundername: Robert Wood Johnson Foundation funderid: CTSC KL2 – fundername: National Center for Advancing Translational Sciences funderid: UL1 TR000002 ; CTSC KL2 ; UL1 TR001860 – fundername: National Center for Advancing Translational Sciences (NCATS) – fundername: VA Merit Review funderid: I01 BX000576 ; I01CX001490 – fundername: BLRD VA grantid: I01 BX000576 – fundername: NHLBI NIH HHS grantid: R01 HL085844 – fundername: NHLBI NIH HHS grantid: R01 HL137228 – fundername: NHLBI NIH HHS grantid: R01 HL085727 – fundername: CSRD VA grantid: I01 CX001490 – fundername: NCATS NIH HHS grantid: KL2 TR000134 – fundername: NCATS NIH HHS grantid: UL1 TR001860 |
| GroupedDBID | --- .3N .GA 05W 0R~ 10A 1L6 1OC 29B 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 SUPJJ SV3 TEORI UB1 V2E W8V W99 WBKPD WHWMO WIH WIJ WIK WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 ~IA ~WT .GJ .Y3 31~ 53G AAMMB AANHP AAQQT AAYXX ACBWZ ACRPL ACYXJ ADNMO AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AZFZN CITATION FEDTE HF~ HVGLF O8X ZGI CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c4433-998f6e04886e9e1243d0ab695cd509f8dd718465675835e9b0733362b00e77c63 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 18 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000434955000030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1522-1946 1522-726X |
| IngestDate | Tue Nov 04 01:44:53 EST 2025 Sun Nov 09 11:48:11 EST 2025 Sat Nov 29 14:24:55 EST 2025 Thu Apr 03 07:06:12 EDT 2025 Sat Nov 29 03:33:08 EST 2025 Tue Nov 18 21:08:20 EST 2025 Wed Jan 22 16:48:39 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | peripheral arterial disease genetics antiplatelet therapy |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2018 Wiley Periodicals, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4433-998f6e04886e9e1243d0ab695cd509f8dd718465675835e9b0733362b00e77c63 |
| Notes | Funding information American Heart Association Clinical Research Award, NIH, Grant/Award Number: R01 HL085727, R01 HL137228, and R01 HL085844; VA Merit Review, Grant/Award Number: I01 BX000576 and I01CX001490; Robert Wood Johnson Foundation, CTSC KL2; National Center for Advancing Translational Sciences, Grant/Award Number: UL1 TR000002, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Grant/Award Number: UL1 TR000002, UL1 TR001860. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-5457-4881 0000-0002-5682-8363 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/5997520 |
| PMID | 29411531 |
| PQID | 2053564187 |
| PQPubID | 986345 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5997520 proquest_miscellaneous_1999199900 proquest_journals_2053564187 pubmed_primary_29411531 crossref_primary_10_1002_ccd_27453 crossref_citationtrail_10_1002_ccd_27453 wiley_primary_10_1002_ccd_27453_CCD27453 |
| PublicationCentury | 2000 |
| PublicationDate | June 1, 2018 |
| PublicationDateYYYYMMDD | 2018-06-01 |
| PublicationDate_xml | – month: 06 year: 2018 text: June 1, 2018 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Washington |
| PublicationTitle | Catheterization and cardiovascular interventions |
| PublicationTitleAlternate | Catheter Cardiovasc Interv |
| PublicationYear | 2018 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2002; 14 1999; 25 Suppl 2 2004; 148 2006; 95 2007; 128 2017; 69 2013; 127 2013; 61 2007; 120 1999; 25 2005; 118 1958; 53 2011; 53 2010; 122 2008; 6 2008; 99 2008; 52 2011; 58 2011; 17 1996; 35 2009; 119 2001; 104 2001; 103 2003; 54 2012; 131 1997; 349 2011; 128 2009; 75 1993; 71 2008; 29 1997; 78 2005; 95 2014; 37 2007; 61 2009; 360 2007; 5 1999; 353 2003; 41 1998; 31 2006; 367 1998; 79 e_1_2_9_30_1 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_12_1 e_1_2_9_33_1 Lepantalo A (e_1_2_9_19_1) 2006; 95 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_18_1 Savcic M (e_1_2_9_43_1) 1999; 25 e_1_2_9_41_1 e_1_2_9_42_1 e_1_2_9_20_1 e_1_2_9_40_1 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 Thebault JJ (e_1_2_9_44_1) 1999; 25 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_27_1 e_1_2_9_29_1 29894588 - Catheter Cardiovasc Interv. 2018 Jun;91(7):1318-1319. doi: 10.1002/ccd.27649 |
| References_xml | – volume: 29 start-page: 992 year: 2008 end-page: 1000 article-title: Prognostic significance of post‐clopidogrel platelet reactivity assessed by a point‐of‐care assay on thrombotic events after drug‐eluting stent implantation publication-title: Eur Heart J – volume: 41 start-page: 961 year: 2003 end-page: 965 article-title: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease publication-title: J Am Coll Cardiol – volume: 349 start-page: 385 year: 1997 end-page: 388 article-title: PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis publication-title: Lancet – volume: 5 start-page: 1839 year: 2007 end-page: 1847 article-title: Different methodologies for evaluating the effect of clopidogrel on platelet function in high‐risk coronary artery disease patients publication-title: J Thromb Haemost – volume: 360 start-page: 2249 year: 2009 end-page: 2250 article-title: Cytochrome P‐450 polymorphisms and response to clopidogrel publication-title: N Engl J Med – volume: 360 start-page: 363 issue: 4 year: 2009 end-page: 375 article-title: Genetic determinants of response to clopidogrel and cardiovascular events publication-title: N Engl J Med – volume: 120 start-page: 631 year: 2007 end-page: 635 article-title: Aspirin resistance and adverse clinical events in patients with coronary artery disease publication-title: Am J Med – volume: 25 Suppl 2 start-page: 3 year: 1999 end-page: 8 article-title: Single‐dose pharmacodynamics of clopidogrel publication-title: Semin Thromb Hemost – volume: 79 start-page: 8 year: 1998 end-page: 13 article-title: Association of a common polymorphism in the factor XIII gene with myocardial infarction publication-title: Thromb Haemost – volume: 367 start-page: 606 year: 2006 end-page: 617 article-title: Aspirin resistance publication-title: Lancet – volume: 61 start-page: 826 year: 2007 end-page: 834 article-title: The genetics of aspirin resistance publication-title: Int J Clin Pract – volume: 52 start-page: 1128 year: 2008 end-page: 1133 article-title: Point‐of‐care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA‐PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty‐Platelet Reactivity Predicts Outcome) study publication-title: J Am Coll Cardiol – volume: 128 start-page: 307 year: 2011 end-page: 316 article-title: Pharmacogenomics of clopidogrel: Evidence and perspectives publication-title: Thromb Res – volume: 37 start-page: 631 year: 2014 end-page: 638 article-title: Prevalence of nonresponsiveness to aspirin in patients with symptomatic peripheral arterial disease using true point of care testing publication-title: Cardiovasc Intervent Radiol – volume: 14 start-page: 51 year: 2002 end-page: 58 article-title: Aspirin resistance and genetic polymorphisms publication-title: J Thromb Thrombolysis – volume: 6 start-page: 2035 issue: 12 year: 2008 end-page: 2044 article-title: Aspirin “resistance”: Role of pre‐existent platelet reactivity and correlation between tests publication-title: J Thromb Haemost – volume: 69 start-page: e71 year: 2017 end-page: e126 article-title: 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines publication-title: J Am Coll Cardiol – volume: 75 start-page: 1 year: 2009 end-page: 18 article-title: The genetics of antiplatelet drug resistance publication-title: Clin Genet – volume: 119 start-page: 237 issue: 2 year: 2009 end-page: 242 article-title: Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point‐of‐care assay. A 12‐month follow‐up publication-title: Circulation – volume: 353 start-page: 351 year: 1999 end-page: 354 article-title: Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: A case–control study publication-title: Lancet – volume: 99 start-page: 409 year: 2008 end-page: 415 article-title: The use of the VerifyNow P2Y12 point‐of‐care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration publication-title: Thromb Haemost – volume: 58 start-page: 2020 year: 2011 end-page: 2045 article-title: 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines publication-title: J Am Coll Cardiol – volume: 17 start-page: 110 year: 2011 end-page: 116 article-title: Paraoxonase‐1 is a major determinant of clopidogrel efficacy publication-title: Nat Med – volume: 95 start-page: 805 year: 2005 end-page: 808 article-title: Aspirin resistance and a single gene publication-title: Am J Cardiol – volume: 103 start-page: E33 year: 2001 end-page: E34 article-title: Platelet glycoprotein IIIa pl(a) polymorphism and effects of aspirin on thrombin generation publication-title: Circulation – volume: 53 start-page: 668 year: 2011 end-page: 675 article-title: Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients publication-title: J Vasc Surg – volume: 104 start-page: 140 year: 2001 end-page: 144 article-title: Platelet glycoprotein IIIa Pl(a) polymorphism, fibrinogen, and platelet aggregability: The Framingham Heart Study publication-title: Circulation – volume: 35 start-page: 586 year: 1996 end-page: 589 article-title: Structural organization of the human PON1 gene publication-title: Genomics – volume: 61 start-page: 2428 year: 2013 end-page: 2434 article-title: Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: The PRECLOP study: Clinical impact and optimal cutoff value of on‐treatment high platelet reactivity publication-title: J Am Coll Cardiol – volume: 25 start-page: 15 issue: Suppl 2 year: 1999 end-page: 19 article-title: Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects publication-title: Semin Thromb Hemost – volume: 118 start-page: 723 year: 2005 end-page: 727 article-title: Low‐dose aspirin increases aspirin resistance in patients with coronary artery disease publication-title: Am J Med – volume: 95 start-page: 253 year: 2006 end-page: 259 article-title: Polymorphisms of COX‐1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients publication-title: Thromb Haemost – volume: 53 start-page: 457 year: 1958 end-page: 481 article-title: Nonparametric estimation from incomplete observations publication-title: J. Am. Stat. Assoc. – volume: 78 start-page: 1003 year: 1997 end-page: 1007 article-title: Variable platelet response to low‐dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty publication-title: Thromb Haemost – volume: 127 start-page: 1425 year: 2013 end-page: 1443 article-title: Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines publication-title: Circulation – volume: 148 start-page: 263 year: 2004 end-page: 268 article-title: Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high‐risk primary prevention: Rationale and design of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial publication-title: Am Heart J – volume: 54 start-page: 371 year: 2003 end-page: 392 article-title: Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism publication-title: Annu Rev Med – volume: 131 start-page: 653 year: 2012 end-page: 664 article-title: Recent advances in the pharmacogenetics of clopidogrel publication-title: Hum Genet – volume: 360 start-page: 354 issue: 4 year: 2009 end-page: 362 article-title: Cytochrome P‐450 polymorphisms and response to clopidogrel publication-title: N Engl J Med – volume: 31 start-page: 329 year: 1998 end-page: 336 article-title: Human serum paraoxonase publication-title: Gen Pharmacol – volume: 122 start-page: 2183 year: 2010 end-page: 2200 article-title: Lipoprotein‐associated and secreted phospholipases A(2) in cardiovascular disease: Roles as biological effectors and biomarkers publication-title: Circulation – volume: 128 start-page: 143 year: 2007 end-page: 149 article-title: Comparison of different methods to evaluate the effect of aspirin on platelet function in high‐risk patients with ischemic heart disease receiving dual antiplatelet treatment publication-title: Am J Clin Pathol – volume: 71 start-page: 397 year: 1993 end-page: 403 article-title: Two‐year follow‐up of aspirin responder and aspirin non responder. A pilot‐study including 180 post‐stroke patients publication-title: Thromb Res – ident: e_1_2_9_22_1 doi: 10.1111/j.1742-1241.2007.01344.x – ident: e_1_2_9_41_1 doi: 10.1111/j.1538-7836.2007.02656.x – ident: e_1_2_9_14_1 doi: 10.1016/j.amjmed.2005.03.041 – volume: 25 start-page: 15 issue: 2 year: 1999 ident: e_1_2_9_43_1 article-title: Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects publication-title: Semin Thromb Hemost – ident: e_1_2_9_26_1 doi: 10.1038/nm.2281 – ident: e_1_2_9_39_1 doi: 10.1111/j.1538-7836.2008.03184.x – ident: e_1_2_9_35_1 doi: 10.1146/annurev.med.54.101601.152421 – ident: e_1_2_9_23_1 doi: 10.1056/NEJMc090391 – ident: e_1_2_9_20_1 doi: 10.1016/j.amjcard.2004.11.045 – ident: e_1_2_9_31_1 doi: 10.1007/s00270-013-0710-3 – ident: e_1_2_9_40_1 doi: 10.1160/TH07-09-0575 – ident: e_1_2_9_7_1 doi: 10.1093/eurheartj/ehn046 – volume: 25 start-page: 3 year: 1999 ident: e_1_2_9_44_1 article-title: Single‐dose pharmacodynamics of clopidogrel publication-title: Semin Thromb Hemost – ident: e_1_2_9_32_1 doi: 10.1016/j.jacc.2013.03.036 – ident: e_1_2_9_21_1 doi: 10.1055/s-0037-1614250 – ident: e_1_2_9_29_1 doi: 10.1002/cncr.21979 – ident: e_1_2_9_9_1 doi: 10.1016/j.jacc.2008.06.038 – ident: e_1_2_9_3_1 doi: 10.1161/CIR.0b013e31828b82aa – ident: e_1_2_9_34_1 doi: 10.1006/geno.1996.0401 – ident: e_1_2_9_17_1 doi: 10.1161/01.CIR.104.2.140 – ident: e_1_2_9_13_1 doi: 10.1111/j.1399-0004.2008.01105.x – ident: e_1_2_9_36_1 doi: 10.1016/S0306-3623(98)00028-7 – ident: e_1_2_9_24_1 doi: 10.1056/NEJMoa0808227 – ident: e_1_2_9_16_1 doi: 10.1161/01.CIR.103.6.e33 – ident: e_1_2_9_25_1 doi: 10.1056/NEJMoa0809171 – ident: e_1_2_9_2_1 doi: 10.1016/j.jacc.2011.08.023 – ident: e_1_2_9_4_1 doi: 10.1016/j.jacc.2016.11.007 – ident: e_1_2_9_10_1 doi: 10.1016/j.thromres.2011.04.010 – ident: e_1_2_9_38_1 doi: 10.1309/0G1PEJ00J8KP8357 – ident: e_1_2_9_42_1 doi: 10.1161/CIRCULATIONAHA.108.812636 – volume: 95 start-page: 253 year: 2006 ident: e_1_2_9_19_1 article-title: Polymorphisms of COX‐1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients publication-title: Thromb Haemost doi: 10.1160/TH05-07-0516 – ident: e_1_2_9_15_1 doi: 10.1016/S0140-6736(97)80010-4 – ident: e_1_2_9_37_1 doi: 10.1161/CIRCULATIONAHA.110.936393 – ident: e_1_2_9_5_1 doi: 10.1016/0049-3848(93)90164-J – ident: e_1_2_9_8_1 doi: 10.1016/j.amjmed.2006.10.021 – ident: e_1_2_9_11_1 doi: 10.1023/A:1022066305399 – ident: e_1_2_9_12_1 doi: 10.1007/s00439-011-1130-6 – ident: e_1_2_9_30_1 doi: 10.1016/j.jvs.2010.08.029 – ident: e_1_2_9_18_1 doi: 10.1016/S0140-6736(98)06448-4 – ident: e_1_2_9_28_1 doi: 10.1016/S0140-6736(06)68040-9 – ident: e_1_2_9_27_1 doi: 10.1016/j.ahj.2004.03.028 – ident: e_1_2_9_33_1 doi: 10.1055/s-0038-1657677 – ident: e_1_2_9_6_1 doi: 10.1016/S0735-1097(02)03014-0 – reference: 29894588 - Catheter Cardiovasc Interv. 2018 Jun;91(7):1318-1319. doi: 10.1002/ccd.27649 |
| SSID | ssj0009629 |
| Score | 2.3287694 |
| Snippet | Objectives
Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on‐treatment platelet reactivity (HoTPR), and... Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse... ObjectivesOur aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on‐treatment platelet reactivity (HoTPR), and... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1308 |
| SubjectTerms | Adult Aged Aged, 80 and over Amputation, Surgical Angiography antiplatelet therapy Arteries Aryldialkylphosphatase - genetics Arylesterase Aspirin Aspirin - adverse effects Aspirin - therapeutic use California - epidemiology Cardiovascular diseases Cerebral infarction Clinical outcomes Clopidogrel Clopidogrel - adverse effects Clopidogrel - therapeutic use Drug Resistance - genetics Drug Therapy, Combination Female genetics Group III Phospholipases A2 - genetics Health risk assessment Humans Limb Salvage Male Middle Aged Myocardial infarction Myocardial Infarction - epidemiology Paraoxonase Patients peripheral arterial disease Peripheral Arterial Disease - diagnosis Peripheral Arterial Disease - drug therapy Peripheral Arterial Disease - epidemiology Peripheral Arterial Disease - genetics Phospholipase A2 Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Platelet Function Tests Platelets Polymorphism, Single Nucleotide Prospective Studies Risk Factors Single-nucleotide polymorphism Stroke - epidemiology Time Factors Treatment Outcome |
| Title | Aspirin and clopidogrel high on‐treatment platelet reactivity and genetic predictors in peripheral arterial disease |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fccd.27453 https://www.ncbi.nlm.nih.gov/pubmed/29411531 https://www.proquest.com/docview/2053564187 https://www.proquest.com/docview/1999199900 https://pubmed.ncbi.nlm.nih.gov/PMC5997520 |
| Volume | 91 |
| WOSCitedRecordID | wos000434955000030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1522-726X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009629 issn: 1522-1946 databaseCode: DRFUL dateStart: 19990101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NatwwEB6STSm9tOlPUrdpUEoPubixZVuy6ClsuuSQhhCSsjdjS7NkYfEuu9mc8wh9xj5JZ2Sv0yUtFHowGOvHQprxfOORvgH4RDbZSSXp61caHabGYVi50oSJNRqZr0V7AtPvZ_r8PB8OzcUGfFmdhWn4IbofbqwZ_nvNCl5Wi6MH0lBr3WdyqbJkE7YkyW3Wg62Ty8H12QPnrvJJyshCyZB8dbUiForkUdd43Rw9wpiPt0r-DmG9DRq8-K_Rb8PzFnqK40ZWXsIG1q_g6bc2uP4alsccdR_XoqydsHySyk3JG58IpjQW0_rn_Y9uW7qYTQik0poLemKbDBS-HckjH4sUszn3y6l8BPXIdMqev2Ai_B5SEnrRhobewPXg61X_NGyzMoQ2TZMkJP9spJAVX6FBggeJi8pKmcw6Ah-j3Dkyd8zCRp5IkqGpOC0kmUnSb9TaqmQHevW0xrcgVGQJTVZxFSub4igy0ocFEeMMUeMogMPV4hS2pSznzBmToiFblgVNY-GnMYCPXdVZw9Pxp0p7qxUuWlVdFJIZblQa5zqAg66YlIwjJ2WN0-WiYK4GvqIogN1GILq3SJMSqk7iAPSaqHQVmMB7vaQe33gi78wYnUnq89CLyt8HXvT7J_7m3b9XfQ_PCNzlzba2Pejdzpf4AZ7Yu9vxYr4Pm3qY77ca8wsDYhoz |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fb9MwED-NDTFe-M8IDDCIh72EJU5i1xIvU0c1RFchtKG9WYl9FZWqtGpXnvkIfEY-CXdOmlENJCQeIkWx40TxXe53vvPvAN6QTfZSSfr7lUbHufEYV740ceaMRuZr0YHA9MtQj0a9iwvzaQverffCNPwQ3YIba0b4X7OC84L04RVrqHP-LflURXYDdnISI5LvnePPg_PhFemuClXKyETJmJx1tWYWSuRhd_OmPboGMq_nSv6OYYMRGtz9v9e_B3da8CmOGmm5D1tYP4Bbp214_SGsjjjuPqlFWXvheC-Vn5E_PhVMaixm9c_vP7rEdDGfEkylWRd0xTU1KMJ9JJG8MVLMFzwuF_MRNCITKgcGg6kIWaQk9qINDj2C88H7s_5J3NZliF2eZ1lMHtpYIau-QoMEEDKflJUyhfMEP8Y978ngMQ8b-SJZgabiwpBkKEnDUWunssewXc9qfAJCJY7wZJVWqXI5jhMjQ2AQMS0QNY4jOFjPjnUtaTnXzpjahm5ZWvqMNnzGCF53XecNU8efOu2vp9i2yrq0kjluVJ72dASvumZSM46dlDXOVkvLbA18JEkEe41EdE-RJidcnaUR6A1Z6TowhfdmSz35Gqi8C2N0IWnMgyArf39x2-8fh5On_971JeyenJ0O7fDD6OMzuE1Qr9ckue3D9uVihc_hpvt2OVkuXrSK8wsuax07 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB6VFFVcKG8MBRbEoRdTP3ezUi9VQgQiRBWiqLeVvTsWkSInShrO_AR-I7-EmbXjNmqRkDhYsrwPr3ZnPN94dr8BeEs22SUyoa9foVWYaYdh6QodplYrZL4W5QlMv43VZNI_P9enO3C8OQvT8EN0P9xYM_z3mhUcF646umQNtda9I58qT2_BbsZJZHqwO_wyOhtfku5Kn6WMTFQSkrMuN8xCUXLUNd62R9dA5vW9klcxrDdCo_3_G_49uNuCT3HSSMt92MH6Aex9bsPrD2F9wnH3aS2K2gnLZ6ncnPzxmWBSYzGvf__81W1MF4sZwVRadUFPbJODwrcjieSDkWKx5H45mY-gHplQ2TMYzITfRUpiL9rg0CM4G73_OvgQtnkZQptlaRqSh1ZJZNWXqJEAQuqiopQ6t47gR9V3jgwe87CRL5LmqEtODEmGkjQclbIyfQy9el7jUxAysoQny7iMpc2winTiA4OIcY6osArgcLM6xrak5Zw7Y2YauuXE0DQaP40BvOmqLhqmjpsqHWyW2LTKujIJc9zILO6rAF53xaRmHDspapyvV4bZGviKogCeNBLRvSXRGeHqNA5AbclKV4EpvLdL6ul3T-Wda63yhPo89LLy94GbwWDob579e9VXsHc6HJnxx8mn53CHkF6_2eN2AL2L5RpfwG3742K6Wr5s9eYPkNIctg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Aspirin+and+clopidogrel+high+on-treatment+platelet+reactivity+and+genetic+predictors+in+peripheral+arterial+disease&rft.jtitle=Catheterization+and+cardiovascular+interventions&rft.au=Yeo%2C+Khung-Keong&rft.au=Armstrong%2C+Ehrin+J.&rft.au=L%C3%B3pez%2C+Javier+E.&rft.au=Chen%2C+Debbie+C.&rft.date=2018-06-01&rft.issn=1522-1946&rft.eissn=1522-726X&rft.volume=91&rft.issue=7&rft.spage=1308&rft.epage=1317&rft_id=info:doi/10.1002%2Fccd.27453&rft_id=info%3Apmid%2F29411531&rft.externalDocID=PMC5997520 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-1946&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-1946&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-1946&client=summon |